Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNA Allena Pharmaceuticals, Inc. daily Stock Chart
ALNA [NASD]
Allena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own8.27% Shs Outstand21.64M Perf Week7.39%
Market Cap141.53M Forward P/E- EPS next Y-1.88 Insider Trans- Shs Float19.09M Perf Month-6.17%
Income-35.60M PEG- EPS next Q-0.49 Inst Own88.40% Short Float1.01% Perf Quarter-21.39%
Sales- P/S- EPS this Y-63.30% Inst Trans0.09% Short Ratio4.91 Perf Half Y-37.71%
Book/sh2.38 P/B2.75 EPS next Y-0.50% ROA-46.60% Target Price30.43 Perf Year-52.88%
Cash/sh- P/C- EPS next 5Y- ROE-56.90% 52W Range4.80 - 17.26 Perf YTD20.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.11% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low36.25% ATR0.36
Employees49 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)47.77 Volatility6.70% 4.86%
OptionableNo Debt/Eq0.20 EPS Q/Q-42.70% Profit Margin- Rel Volume0.31 Prev Close6.35
ShortableYes LT Debt/Eq0.20 EarningsMar 26 BMO Payout- Avg Volume39.19K Price6.54
Recom1.50 SMA20-2.04% SMA50-3.80% SMA200-25.23% Volume12,333 Change2.99%
Jan-18-19Initiated Robert W. Baird Outperform $20
Dec-21-18Resumed B. Riley FBR Buy
Nov-08-18Resumed Jefferies Buy
Apr-25-18Initiated B. Riley FBR, Inc. Buy $23.50
Apr-02-18Initiated ROTH Capital Buy $61
Apr-17-19 09:02AM  Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52% Simply Wall St.
08:01AM  Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors GlobeNewswire
Mar-27-19 08:00AM  Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial GlobeNewswire
Mar-07-19 08:01AM  Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-05-19 08:00AM  Allena Pharmaceuticals, Inc. to Present at 39th Annual Cowen & Co. Health Care Conference GlobeNewswire
Jan-04-19 08:00AM  Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019 GlobeNewswire +8.15%
Jan-02-19 08:00AM  Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria GlobeNewswire +17.98%
Dec-23-18 09:21PM  Do Hedge Funds Love Allena Pharmaceuticals, Inc. (ALNA)? Insider Monkey
Nov-19-18 08:25AM  Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -5.11%
Nov-07-18 08:00AM  Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-06-18 04:01PM  Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November GlobeNewswire
Oct-25-18 08:00AM  Allena Pharmaceuticals to Present Data Characterizing Significant Unmet Need in Enteric Hyperoxaluria at ASN Kidney Week 2018 GlobeNewswire -5.17%
Oct-22-18 08:00AM  Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346 GlobeNewswire
Oct-18-18 08:00AM  Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings GlobeNewswire
Sep-25-18 08:00AM  Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October GlobeNewswire
Aug-07-18 04:01PM  Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire -6.09%
08:00AM  Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-27-18 07:36AM  Allena Pharmaceuticals Enters Oversold Territory Zacks
Jul-12-18 07:48AM  Allena Pharmaceuticals (ALNA) Enters Oversold Territory Zacks
Jun-19-18 08:00AM  Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease GlobeNewswire
Jun-11-18 08:00AM  Allena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors GlobeNewswire
May-30-18 08:00AM  Allena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference GlobeNewswire
May-08-18 08:00AM  Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Apr-20-18 05:54PM  Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear? Simply Wall St.
Apr-04-18 11:21AM  Allena Pharmaceuticals (ALNA) Enters Overbought Territory Zacks
Mar-30-18 02:31PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-27-18 08:00AM  Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire +7.68%
Mar-07-18 08:00AM  Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire +12.10%
Mar-06-18 08:00AM  Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria GlobeNewswire
Feb-23-18 03:03PM  Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)? Simply Wall St.
Feb-14-18 09:38PM  Pharmstandard International S.A. Buys Allena Pharmaceuticals Inc GuruFocus.com
Feb-05-18 10:00AM  Allena Pharmaceuticals, Inc. (Nasdaq: ALNA) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Nov-24-17 02:25PM  What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)? Simply Wall St.
Nov-09-17 07:35PM  Allena Pharmaceuticals Inc (ALNA): Time For A Financial Health Check Simply Wall St.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.